Onderzoeker
Sandrine Aspeslagh
- Trefwoorden:Geneeskunde
Affiliaties
- Interne Geneeskunde (Departement)
Lid
Vanaf1 mei 2023 → Heden - Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Medische Oncologie (Departement)
Lid
Vanaf1 feb 2019 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 feb 2021 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 feb 2021 → 20 okt 2022 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 nov 2020 → 14 nov 2022
Projecten
1 - 1 of 1
- FORX – voedingsinterventies ter reductie van toxiciteit van immuuntherapieVanaf1 nov 2023 → HedenFinanciering: FWO mandaten
Publicaties
1 - 10 van 71
- Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors(2024)
Auteurs: Stephanie C M Wuyts, Charlotte Annette Cappelle, Marthe Verhaert, Bert Bravenboer, Sandrine Aspeslagh
Pagina's: 55-66 - Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Auteurs: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pagina's: 1378-1384 - Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus(2023)
Auteurs: Valérie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crapé, Michael Somers, et al.
Pagina's: 36-57 - Recommendations of the International Society of Geriatric Oncology on skin cancer management in older patients(2023)
Auteurs: Agata Rembielak, Thomas Yau, Baran Akagunduz, Sandrine Aspeslagh, Giuseppe Colloca, Aoife Conway, Falalu Danwata, Veronique Del Marmol, Chuck O'Shea, Marthe Verhaert, et al.
- Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review(2023)
Auteurs: Mariana Brandão, Valérie Durieux, Maša Auprih, Alessandra Fozza, Nicolas Dauby, Francesco Cuccia, Sandrine Aspeslagh, Marthe Verhaert, Niccolò Giaj-Levra
Pagina's: 75-86 - First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)(2023)
Auteurs: Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H.m. Schellens, Jennifer K Litton, Sandrine Aspeslagh, et al.
- Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma(2023)
Auteurs: Emiel A De Jaeghere, Sandra Tuyaerts, An Van Nuffel, Ann Belmans, Kris Bogaerts, Regina E. M. Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, xuan bich trinh, et al.
Pagina's: 475-491 - Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient(2023)
Auteurs: Marthe Verhaert, Jeroen Mebis, Sandrine Aspeslagh, Berlinde von Kemp
- Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab(2022)
Auteurs: Sylvain Raoul Simeni Njonnou, Sandrine Aspeslagh, Marie-Josiane Ntsama Essomba, Marie-Lucie Racu, Fernando Kemta Lekpa, Frédéric Vandergheynst
- Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19(2022)
Auteurs: Tatjana Geukens, M. Brandão, A Laenen, Joelle Collignon, C Van Marcke, Ingrid Louviaux, Wim Demey, S Van Wambeke, Dirk Schrijvers, S LECOMTE, et al.